US drug major Merck & Co's third-quarter 2008 earnings per share dropped 27.1% year-on-year to $0.51 due to a heavy $0.29 per share restructuring charge and slightly lower sales. Net income fell 28.2% to $1.09 billion.
On the day the results were reported, October 22, Merck shares closed down 6.6% to $28.01, as the firm announced plans to implement another cost-cutting program in a bid to lose 7,200 positions by the end of 2011, with 40% of the total job cuts to take place in the USA. As part of this latest wave of downsizing, Merck plans to reduce its total number of senior and mid-level executives by 25%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze